Glass Wealth Management Co LLC Buys 50 Shares of Amgen Inc. $AMGN

Glass Wealth Management Co LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 7.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 755 shares of the medical research company’s stock after acquiring an additional 50 shares during the quarter. Glass Wealth Management Co LLC’s holdings in Amgen were worth $211,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Global Assets Advisory LLC lifted its holdings in shares of Amgen by 5.6% during the second quarter. Global Assets Advisory LLC now owns 2,930 shares of the medical research company’s stock valued at $851,000 after acquiring an additional 155 shares during the period. Merit Financial Group LLC lifted its holdings in shares of Amgen by 20.1% during the second quarter. Merit Financial Group LLC now owns 24,325 shares of the medical research company’s stock valued at $6,792,000 after acquiring an additional 4,073 shares during the period. Keudell Morrison Wealth Management lifted its holdings in shares of Amgen by 7.1% during the second quarter. Keudell Morrison Wealth Management now owns 5,295 shares of the medical research company’s stock valued at $1,478,000 after acquiring an additional 352 shares during the period. Beacon Financial Advisory LLC lifted its holdings in shares of Amgen by 13.6% during the second quarter. Beacon Financial Advisory LLC now owns 978 shares of the medical research company’s stock valued at $273,000 after acquiring an additional 117 shares during the period. Finally, IVC Wealth Advisors LLC lifted its holdings in shares of Amgen by 27.3% during the second quarter. IVC Wealth Advisors LLC now owns 1,445 shares of the medical research company’s stock valued at $404,000 after acquiring an additional 310 shares during the period. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on AMGN shares. Bank of America raised their target price on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday, September 26th. Raymond James Financial started coverage on Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating for the company. William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. Cantor Fitzgerald restated a “neutral” rating and issued a $305.00 target price on shares of Amgen in a research note on Tuesday, June 24th. Finally, Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Friday. Seven equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and an average target price of $309.70.

Amgen Trading Up 0.2%

NASDAQ:AMGN opened at $297.89 on Monday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $335.88. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The business has a 50 day moving average price of $287.34 and a two-hundred day moving average price of $287.98. The company has a market cap of $160.37 billion, a P/E ratio of 24.36, a price-to-earnings-growth ratio of 2.59 and a beta of 0.49.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the prior year, the firm posted $4.97 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were issued a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s dividend payout ratio is presently 77.84%.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.